Study details
Enrolling now
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
SynAct Pharma Aps
NCT IDNCT06671054ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
240
Study length
about 1.2 years
Ages
18+
Locations
3 sites in FL, PA
About this study
Researchers are testing different doses of a medication called AP1189 to see if it helps with early rheumatoid arthritis. The trial will last for 456 days and involve participants who have never taken DMARDs before.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AP1189 matching placebo
- 2.Take AP1189, 100 mg
- 3.Take AP1189, 40 mg
- +1 more
PhasePhase 2
Primary goalChange in Disease Activity Score 28 (DAS28)-C-Reactive Protein (CRP)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change in Disease Activity Score 28 (DAS28)-C-Reactive Protein (CRP)
Body systems
Immune